Comparison of Robotic vs Open Cystectomy: A Systematic Review.

Bladder cancer complications cystectomy quality of life robotic surgical procedures

Journal

Bladder cancer (Amsterdam, Netherlands)
ISSN: 2352-3735
Titre abrégé: Bladder Cancer
Pays: Netherlands
ID NLM: 101668567

Informations de publication

Date de publication:
2023
Historique:
received: 12 07 2022
accepted: 04 09 2023
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

The benefits of a robot-assisted radical cystectomy (RARC) compared to an open approach is still under debate. Initial data on RARC were from trials where urinary diversion was performed by an extracorporeal approach, which does not represent a completely minimally invasive procedure. There are now updated data for RARC with intracorporeal urinary diversion that add to the evidence profile of RARC. To perform a systematic review and meta-analysis of the effectiveness of RARC compared with open radical cystectomy (ORC). Multiple databases were searched up to May 2022. We included randomised trials in which patients underwent RARC and ORC. Oncological and safety outcomes were assessed. Seven trials of 907 participants were included. There were no differences seen in primary outcomes: disease progression [RR 0.98, 95% CI 0.78 to 1.23], major complications [RR 0.95, 95% CI 0.72 to 1.24] and quality of life [SMD 0.05, 95% CI -0.13 to 0.38]. RARC resulted in a decreased risk of perioperative blood transfusion [RR 0.57, 95% CI 0.43 to 0.76], wound complications [RR 0.34, 95% CI 0.21 to 0.55] and reduced length of hospital stay [MD -0.62 days, 95% CI -1.11 to -0.13]. However, there was an increased risk of developing a ureteric stricture [RR 4.21, 95% CI 1.07 to 16.53] in the RARC group and a prolonged operative time [MD 70.4 minutes, 95% CI 34.1 to 106.7]. The approach for urinary diversion did not impact outcomes. RARC is an oncologically safe procedure compared to ORC and provides the benefits of a minimally invasive approach. There was an increased risk of developing a ureteric stricture in patients undergoing RARC that warrants further investigation. There was no difference in oncological outcomes between approaches.

Sections du résumé

BACKGROUND BACKGROUND
The benefits of a robot-assisted radical cystectomy (RARC) compared to an open approach is still under debate. Initial data on RARC were from trials where urinary diversion was performed by an extracorporeal approach, which does not represent a completely minimally invasive procedure. There are now updated data for RARC with intracorporeal urinary diversion that add to the evidence profile of RARC.
OBJECTIVE OBJECTIVE
To perform a systematic review and meta-analysis of the effectiveness of RARC compared with open radical cystectomy (ORC).
MATERIALS AND METHODS METHODS
Multiple databases were searched up to May 2022. We included randomised trials in which patients underwent RARC and ORC. Oncological and safety outcomes were assessed.
RESULTS RESULTS
Seven trials of 907 participants were included. There were no differences seen in primary outcomes: disease progression [RR 0.98, 95% CI 0.78 to 1.23], major complications [RR 0.95, 95% CI 0.72 to 1.24] and quality of life [SMD 0.05, 95% CI -0.13 to 0.38]. RARC resulted in a decreased risk of perioperative blood transfusion [RR 0.57, 95% CI 0.43 to 0.76], wound complications [RR 0.34, 95% CI 0.21 to 0.55] and reduced length of hospital stay [MD -0.62 days, 95% CI -1.11 to -0.13]. However, there was an increased risk of developing a ureteric stricture [RR 4.21, 95% CI 1.07 to 16.53] in the RARC group and a prolonged operative time [MD 70.4 minutes, 95% CI 34.1 to 106.7]. The approach for urinary diversion did not impact outcomes.
CONCLUSION CONCLUSIONS
RARC is an oncologically safe procedure compared to ORC and provides the benefits of a minimally invasive approach. There was an increased risk of developing a ureteric stricture in patients undergoing RARC that warrants further investigation. There was no difference in oncological outcomes between approaches.

Identifiants

pubmed: 38993188
doi: 10.3233/BLC-220065
pii: BLC220065
pmc: PMC11181804
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Pagination

253-269

Informations de copyright

© 2023 – The authors. Published by IOS Press.

Déclaration de conflit d'intérêts

Konety and Lawrentschuk are Editorial Board members of this journal, but were not involved in the peer-review process nor had access to any information regarding its peer-review. Sathianathen, Pan, Furrer, Thomas, Dundee, Corcoran, Weight and Nair have no conflict of interest to report.

Auteurs

Niranjan J Sathianathen (NJ)

Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.

Henry Y C Pan (HYC)

Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.

Marc Furrer (M)

Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.
Department of Urology, University of Bern, Inselspital, Bern, Switzerland.
Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Benjamin Thomas (B)

Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.

Philip Dundee (P)

Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.

Niall Corcoran (N)

Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.
Department of Urology, Western Health, Footscray, VIC, Australia.
Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.

Christopher J Weight (CJ)

Department of Urology, Cleveland Clinic, Cleveland, OH, USA.

Badrinath Konety (B)

Department of Urology, Allina Health, Minneapolis, MN, USA.

Rajesh Nair (R)

Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Nathan Lawrentschuk (N)

Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.
Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.

Classifications MeSH